Condition (MeSH)
Extravasation of Diagnostic and Therapeutic Materials
ClinicalTrials.gov lists 28 trials for Extravasation of Diagnostic and Therapeutic Materials or a narrower condition beneath it. Biogen has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
8 of the 28 trials are tagged with Extravasation of Diagnostic and Therapeutic Materials itself; the rest are tagged with a narrower condition beneath it.
When did Extravasation of Diagnostic and Therapeutic Materials trials start? (15)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 2 |
| 2024 | 1 |
| 2023 | 3 |
| 2022 | 1 |
| 2021 | 5 |
| 2018 | 1 |
| 2017 | 4 |
| 2016 | 2 |
| 2015 | 3 |
| 2013 | 1 |
Showing 10 of 15 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 28 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Extravasation of Diagnostic and Therapeutic Materials trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 1 |
| Phase 4 | 8 |
| Not applicable | 7 |
| Observational | 9 |
How many Extravasation of Diagnostic and Therapeutic Materials trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Active, not recruiting | 2 |
| Completed | 18 |
| Suspended | 1 |
| Terminated | 1 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Extravasation of Diagnostic and Therapeutic Materials trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Biogen | 2 |
| Aspen Global Incorporated | 1 |
| Bursa Yuksek Ihtisas Training and Research Hospital | 1 |
| CW Optics, Inc. | 1 |
| Eitan Medical | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Extravasation of Diagnostic and Therapeutic Materials? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Peginterferon Beta-1a | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| NaCl 0.9% NS | 2 |
| Fluzone-High Dose Quadrivalent | 1 |
| Nalbuphine Sebacate or Sesame oil (placebo) | 1 |
| Shingrix vaccine | 1 |
| Cabotegravir long-acting | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Extravasation of Diagnostic and Therapeutic Materials trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Chest Pain | 2 | 1 |
| Fall | 2 | 1 |
| Small bowel obstruction | 2 | 1 |
| Acute Hyperkalemia | 1 | 1 |
| Acute pulmonary embolism and acute deep vein thrombosis | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Extravasation of Diagnostic and Therapeutic Materials? (93)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| FDG Extravasation in PET/CT Imaging: A Visual Grading Approach Based on Clinical Observations. | Journal of medical imaging and radiation oncology | 2025 | Yes |
| Effect of Extrinsic Warming of Low-Osmolality CT Contrast Media (Iohexol 350) on Extravasations and Patient Reaction Rates: A Retrospective Study. | AJR. American journal of roentgenology | 2022 | Yes |
| Phlebitis and infiltration: vascular trauma associated with the peripheral venous catheter. | Revista latino-americana de enfermagem | 2018 | Yes |
| MRI and CT contrast media extravasation: A systematic review. | Medicine | 2018 | Yes |
| Diagnosis of Intraabdominal Fluid Extravasation After Hip Arthroscopy With Point-of-Care Ultrasonography Can Identify Patients at an Increased Risk for Postoperative Pain. | Anesthesia and analgesia | 2017 | Yes |
Showing 5 of 93 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.